Twenty-five years of shared life with vancomycin-resistant enterococci: Is it time to divorce

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 4, 2013, Pages 731-742

  Cattoir, Vincent ^a,b   Leclercq, Roland ^a,b  

^a UNIVERSITÉ DE CAEN   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Antibiotic resistance; Clonality; MDR; Nosocomial infection; Vancomycin; VRE

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

BACTERIAL COLONIZATION; BACTERIUM ISOLATE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HUMAN; NONHUMAN; PATHOGENICITY; PLASMID; REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS;

CARRIER STATE; CROSS INFECTION; DISEASE OUTBREAKS; DNA, BACTERIAL; ENTEROCOCCUS; GENOTYPE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFECTION CONTROL; VANCOMYCIN RESISTANCE; WORLD HEALTH;

EID: 84875277296     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks469     Document Type: Review

References (109)

1. Uttley AH, Collins CH, Naidoo J et al. Vancomycin-resistant enterococci. Lancet 1988; 1: 57-8.
2. Leclercq R, Derlot E, Duval J et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: 157-61.
3. Frieden TR, Munsiff SS, Low DE et al. Emergence of vancomycinresistant enterococci in New York City. Lancet 1993; 342: 76-9.
4. The European Antimicrobial Resistance Surveillance System. EARSS results. http://www.rivm.nl/earss/result/ (2nd September 2012, date last accessed).
5. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from Lancet Infect Dis 2001; 1: 314-25.
6. Courvalin P. Vancomycin resistance in Gram-positive cocci. Clin Infect Dis 2006; 42 SUPPL 1: S25-34.
7. Acar J, Casewell M, Freeman J et al. Avoparcin and virginiamycin as animal growth promoters: a plea for science in decision-making. Clin Microbiol Infect 2000; 6: 477-82.
8. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72: 195-8.
9. Sievert DM, Rudrik JT, Patel JB et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46: 668-74.
10. McGowan JE. Debate-guidelines for control of glycopeptide-resistant enterococci (GRE) have not yet worked. J Hosp Infect 2004; 57: 281-4.
11. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptides antibiotics. Eur J Clin Microbiol Infect Dis 1989; 8: 943-50.
12. Courvalin P. Glycopeptide and enterococci. In: Courvalin R, Leclercq R, Rice L, eds. Antibiogram. Paris: ESKA, 2009; 285-94.
13. Mainardi JL, Villet R, Bugg TD et al. Evolution of peptidoglycan biosynthesis under the selective pressure of antibiotics in Gram-positive bacteria. FEMS Microbiol Rev 2008; 32: 386-408.
14. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000; 406: 775-81.
15. Boyd DA, Willey BM, Fawcett D et al. Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel D-Ala-D-Ser gene cluster, vanL. Antimicrob Agents Chemother 2008; 52: 2667-72.
16. McKessar SJ, Berry AM, Bell JM et al. Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob Agents Chemother 2000; 44: 3224-8.
17. Xu X, Lin D, Yan G et al. vanM, a new glycopeptide resistance gene cluster found in Enterococcus faecium. Antimicrob Agents Chemother 2010; 54: 4643-7.
18. Lebreton F, Depardieu F, Bourdon N et al. D-Ala-D-Ser VanN-type transferable vancomycin resistance in Enterococcus faecium. Antimicrobial Agents Chemother 2011; 55: 4606-12.
19. Krcméry V, Sefton A. Vancomycin resistance in Gram-positive bacteria other than Enterococcus spp. Int J Antimicrob Agents 2000; 14: 99-105.
20. Dutka-Malen S, Molinas C, Arthur M et al. Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase-related protein necessary for vancomycin resistance. Gene 1992; 112: 53-8.
21. Fraimow HS, Jungkind DL, Lander DWet al. Urinary tract infection with an Enterococcus faecalis isolate that requires vancomycin for growth. Ann Intern Med 1994; 121: 22-6.
22. Van Bambeke F, Chauvel M, Reynolds PE et al. Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants. Antimicrob Agents Chemother 1999; 43: 41-7.
23. Marshall CG, Lessard IA, Park I et al. Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms. Antimicrob Agents Chemother 1998; 42: 2215-20.
24. Patel R, Piper K, Cockerill FR III et al. The biopesticide Paenibacillus popilliae has a vancomycin resistance gene cluster homologous to the enterococcal VanA vancomycin resistance gene cluster. Antimicrob Agents Chemother 2000; 44: 705-9.
25. D'Costa VM, King CE, Kalan L et al. Antibiotic resistance is ancient. Nature 2011; 477: 457-61.
26. Van der Auwera P, Pensart N, Korten V et al. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 1996; 173: 1129-36.
27. Bates J, Jordens Z, Selkon JB. Evidence for an animal origin of vancomycin-resistant enterococci. Lancet 1993; 342: 490-1.
28. Wegener HC, Aarestrup FM, Jensen LB et al. Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Emerg Infect Dis 1999; 5: 329-35.
29. Descheemaeker PRM, Chapelle S, Devriese LA et al. Comparison of glycopeptide resistant Enterococcus faecium isolates and glycopeptide resistance genes of human and animal origins. Antimicrob Agents Chemother 1999; 43: 2032-7.
30. Hammerum AM, Lester CH, Heuer OE. Antimicrobial-resistant enterococci in animals and meat: a human health hazard Foodborne Pathog Dis 2010; 7: 1137-46.
31. Ellis J. Overexploitation of a valuable resource New literature on the precautionary principle. Eur J Int Law 2006; 17: 445-62.
32. Bager F, Aarestrup FM, Madsen M et al. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin. Microb Drug Res 1999; 5: 53-6.
33. Kempf I, Hellard G, Perrin-Guyomard A et al. Prevalence of high-level vancomycin-resistant enterococci in French broilers and pigs. Int J Antimicrob Agents 2008; 32: 463-4.
34. Johnsen PJ, Townsend JP, Bøhn T et al. Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures. J Antimicrob Chemother 2011; 66: 608-10.
35. Centers for Disease Control and Prevention (CDC). Nosocomial enterococci resistant to vancomycin in the United States, 1989-1993. MMWR 1993; 42: 597-9.
36. Grayson ML, Eliopoulos GM, Wennersten CB et al. Increasing resistance to b-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother 1991; 35: 2180-4.
37. Coque TM, Tomayko JF, Ricke SC et al. Vancomycin-resistant enterococci from nosocomial, community and animal sources in the United States. Antimicrob Agents Chermother 1996; 40: 2605-9.
38. Werner G, Coque TM, Hammerum AM et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008; 13: pii:19046.
39. Putnam SD, Sader HS, Moet GJ et al. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagn Microbiol Infect Dis 2010; 67: 359-68.
40. Arias CA, Mendes RE, Stilwell MG et al. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin Infect Dis 2012; 54 SUPPL 3: S233-8.
41. Willems RJ, van Schaik W. Transition of Enterococcus faecium from commensal organism to nosocomial pathogen. Future Microbiol 2009; 4: 1125-35.
42. Ruiz-Garbajosa P, de Regt M, Bonten M et al. High-density fecal Enterococcus faecium colonization in hospitalized patients is associated with the presence of the polyclonal subcluster CC17. Eur J Clin Microbiol Infect Dis 2012; 31: 519-22.
43. Lebreton F, Le Bras F, Reffuveille F et al. Galleria mellonella as a model for studying Enterococcus faecium host persistence. J Mol Microbiol Biotechnol 2011; 21: 191-6.
44. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 2012; 10: 266-78.
45. Lebreton F, van Schaik W, Sanguinetti M et al. AsrR is an oxidative stress sensing regulator modulating Enterococcus faecium opportunistic traits, antimicrobial resistance, and pathogenicity. PLoS Pathog 2012; 8: e1002834.
46. Nallapareddy SR, Weinstock GM, Murray BE. Clinical isolates of Enterococcus faecium exhibit strain-specific collagen binding mediated by Acm, a new member of the MSCRAMM family. Mol Microbiol 2003; 47: 1733-47.
47. Willems RJ, Top J, van Santen M et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 6: 821-8.
48. Qin X, Galloway-Pena JR, Sillanpaa J et al. Complete genome sequence of Enterococcus faecium strain TX16 and comparative genomic analysis of Enterococcus faecium genomes. BMC Microbiol 2012; 12: 135.
49. van Schaik W, Top J, Riley DR et al. Pyrosequencing-based comparative genome analysis of the nosocomial pathogen Enterococcus faecium and identification of a large transferable pathogenicity island. BMC Genomics 2010; 11: 239.
50. Freitas AR, Tedim AP, Novais C et al. Global spread of the hyl(Efm) colonization-virulence gene in megaplasmids of the Enterococcus faecium CC17 polyclonal subcluster. Antimicrob Agents Chemother 2010; 54: 2660-5.
51. Leavis HL, Willems RJ, van Wamel WJ et al. Insertion sequence-driven diversification creates a globally dispersed emerging multiresistant subspecies of E. faecium. PLoS Pathog 2007; 3: e7.
52. Heikens E, Bonten MJ, Willems RJ. Enterococcal surface protein Esp is important for biofilm formation of Enterococcus faecium E1162. J Bacteriol 2007; 189: 8233-40.
53. Leendertse M, Heikens E, Wijnands LM et al. Enterococcal surface protein transiently aggravates Enterococcus faecium-induced urinary tract infection in mice. J Infect Dis 2009; 200: 1162-5.
54. Rice LB, Carias L, Rudin S et al. A potential virulence gene, hylEfm, predominates in Enterococcus faecium of clinical origin. J Infect Dis 2003; 187: 508-12.
55. Bourdon N, Fines-Guyon M, Thiolet JM et al. Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. J Antimicrob Chemother 2011; 66: 713-21.
56. Zervos MJ, Kauffman CA, Therasse PM et al. Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. Ann Intern Med 1987; 106: 687-91.
57. Murray BE. b-lactamase-producing enterococci. Antimicrob Agents Chemother 1992; 36: 2355-9.
58. Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 2001; 7: 183-7.
59. Bérenger R, Bourdon N, Auzou M et al. In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between 2006 and 2008. Med Mal Infect 2011; 41: 405-9.
60. Kainer MA, Devasia RA, Jones TF et al. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis 2007; 13: 1024-30.
61. Arias CA, Panesso D, McGrath DM et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011; 365: 892-900.
62. Top J, Willems R, Blok H et al. Ecological replacement of Enterococcus faecalis by multiresistant clonal complex 17 Enterococcus faecium. Clin Microbiol Infect 2007; 13: 316-9.
63. Institut de Veille Sanitaire. Données par pathoge'ne. March 2012. http:// www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Resistanceaux-anti-infectieux/Donnees-par-pathogene (2 September 2012, date last accessed).
64. Observatoire national de l'épidémiologie de la résistance aux antibiotiques (Onerba): http://www.onerba.org (2 September 2012, date last accessed).
65. Lester CH, Sandvang D, Olsen SS et al. Emergence of ampicillin-resistant Enterococcus faecium in Danish hospitals. J Antimicrob Chemother 2008; 62: 1203-6.
66. Norris AH, Reilly JP, Edelstein PH et al. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995; 20: 1137-44.
67. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36: 473-81.
68. Wilcox MH. Efficacy of linezolid versus comparator therapies in Gram-positive infections. J Antimicrob Chemother 2003; 51 SUPPL 2: 27-35.
69. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346: 867-9.
70. Diaz L, Kiratisin P, Mendes RE et al. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 2012; 56: 3917-22.
71. Cattoir V, Daurel C. Update on antimicrobial chemotherapy. Med Mal Infect 2010; 40: 135-54.
72. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement: Approved Standard M100-S22. CLSI, Wayne, PA, USA, 2012.
73. Cantón R, Ruiz-Garbajosa P, Chaves RL et al. A potential role for daptomycin in enterococcal infections: what is the evidence J Antimicrob Chemother 2010; 65: 1126-36.
74. Vouillamoz J, Moreillon P, Giddey M et al. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 2006; 58: 1208-14.
75. Caron F, Kitzis MD, Gutmann L et al. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother 1992; 36: 2611-6.
76. Sakoulas G, Bayer AS, Pogliano J et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56: 838-44.
77. Mohr JF, Friedrich LV, Yankelev S et al. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009; 33: 543-8.
78. Mave V, Garcia-Diaz J, Islam T et al. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid J Antimicrob Chemother 2009; 64: 175-80.
79. Palmer KL, Daniel A, Hardy C et al. Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 2011; 55: 3345-56.
80. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-7.
81. Azimian A, Havaei SA, Fazeli H et al. Genetic characterization of a vancomycin-resistant Staphylococcus aureus isolated from respiratory tract of a hospitalized patient in a university hospital in North East of Iran. J Clin Microbiol 2012; 50: 3581-5.
82. Banerjee T, Anupurba S. Colonization with vancomycinintermediate Staphylococcus aureus strains containing the vanA resistance gene in a tertiary-care center in North India. J Clin Microbiol 2012; 50: 1730-2.
83. Emaneini M, Aligholi M, Hashemi FB et al. Isolation of vancomycin-resistant Staphylococcus aureus in a teaching hospital in Tehran. J Hosp Infect 2007; 66: 92-3.
84. Saha B, Singh AK, Ghosh A et al. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 2008; 57: 72-9.
85. Kos VN, Desjardins CA, Griggs A et al. Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with methicillin-resistant S. aureus hospital-acquired infection in the United States. MBio 2012; 3: pii:e00112-12.
86. Périchon B, Courvalin P. Synergism between b-lactams and glycopeptides against VanA-type methicillin-resistant Staphylococcus aureus and heterologous expression of the vanA operon. Antimicrob Agents Chemother 2006; 50: 3622-30.
87. Zhu W, Murray PR, Huskins WC et al. Dissemination of an enterococcus Inc18-Like vanA plasmid associated with vancomycinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 4314-20.
88. Corvaglia AR, François P, Hernandez D et al. A type III-like restriction endonuclease functions as a major barrier to horizontal gene transfer in clinical Staphylococcus aureus strains. Proc Natl Acad Sci USA 2010; 107: 11954-8.
89. Foucault ML, Depardieu F, Courvalin P et al. Inducible expression eliminates the fitness cost of vancomycin resistance in enterococci. Proc Natl Acad Sci USA 2010; 107: 16964-9.
90. Foucault ML, Courvalin P, Grillot-Courvalin C. Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 2354-9.
91. Fox PM, Lampen RJ, Stumpf KS et al. Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and b-lactam antibiotics. Antimicrob Agents Chemother 2006; 50: 2951-6.
92. Lepelletier D, Andremont A, Grandbastien B et al. Risk of highly resistant bacteria importation from repatriates and travelers hospitalized in foreign countries: about the French recommendations to limit their spread. J Travel Med 2011; 18: 344-51.
93. Andrighetto C, Knijff E, Lombardi A et al. Phenotypic and genetic diversity of enterococci isolated from Italian cheeses. J Dairy Res 2001; 68: 303-16.
94. Novais C, Coque TM, Costa MJ et al. High occurrence and persistence of antibiotic-resistant enterococci in poultry food samples in Portugal. J Antimicrob Chemother 2005; 56: 1139-43.
95. Gomes BC, Esteves CT, Palazzo IC et al. Prevalence and characterization of Enterococcus spp. isolated from Brazilian foods. Food Microbiol 2008; 25: 668-75.
96. Caplin JL, Hanlon GW, Taylor HD. Presence of vancomycin and ampicillin-resistant Enterococcus faecium of epidemic clonal complex-17 in wastewaters from the south coast of England. Environ Microbiol 2008; 10: 885-92.
97. Macovei L, Miles B, Zurek L. Potential of houseflies to contaminate ready-to-eat food with antibiotic-resistant enterococci. J Food Prot 2008; 71: 435-9.
98. Mallon DJ, Corkill JE, Hazel SM et al. Excretion of vancomycin-resistant enterococci by wild mammals. Emerg Infect Dis 2002; 8: 636-8.
99. Poeta P, Costa D, Igrejas G et al. Phenotypic and genotypic characterization of antimicrobial resistance in faecal enterococci from wild boars (Sus scrofa). Vet Microbiol 2007; 125: 368-74.
100. Drobni M, Bonnedahl J, Hernandez J et al. Vancomycin-resistant enterococci, Point Barrow, Alaska, USA. Emerg Infect Dis 2009; 15: 838-9.
101. Silva N, Igrejas G, Figueiredo N et al. Molecular characterization of antimicrobial resistance in enterococci and Escherichia coli isolates from European wild rabbit (Oryctolagus cuniculus). Sci Total Environ 2010; 408: 4871-6.
102. Stinear TP, Olden DC, Johnson PD et al. Enterococcal vanB resistance locus in anaerobic bacteria in human faeces. Lancet 2001; 357: 855-6.
103. Ballard SA, Pertile KK, Lim M et al. Molecular characterization of vanB elements in naturally occurring gut anaerobes. Antimicrob Agents Chemother 2005; 49: 1688-94.
104. Domingo MC, Huletsky A, Giroux R et al. vanD and vanG-like gene clusters in a Ruminococcus species isolated from human bowel flora. Antimicrob Agents Chemother 2007; 51: 4111-7.
105. Launay A, Ballard SA, Johnson PD et al. Transfer of vancomycin resistance transposon Tn1549 from Clostridium symbiosum to Enterococcus spp. in the gut of gnotobiotic mice. Antimicrob Agents Chemother 2006; 50: 1054-62.
106. Ballard SA, Grabsch EA, Johnson PD et al. Comparison of three PCR primer sets for identification of vanB gene carriage in feces and correlation with carriage of vancomycin-resistant enterococci: interference by vanB-containing anaerobic bacilli. Antimicrob Agents Chemother 2005; 49: 77-81.
107. Bourdon N, Bé Renger R, Lepoultier R et al. Rapid detection of vancomycin-resistant enterococci from rectal swabs by the Cepheid Xpert vanA/vanB assay. Diagn Microbiol Infect Dis 2010; 67: 291-3.
108. Salgado CD, Farr BM. Outcomes associated with vancomycinresistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003; 24: 690-8.
109. Ostrowsky BE, Trick WE, Sohn AH et al. Control of vancomycinresistant enterococcus in health care facilities in a region. N Engl J Med 2001; 344: 1427-33.